Humana (HUM) Aktienübersicht
Humana Inc. bietet medizinische und spezielle Versicherungsprodukte in den Vereinigten Staaten an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 4/6 |
HUM Community Fair Values
Create NarrativeSee what 107 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$212.87
FV
69.5% überbewertet intrinsischer Abschlag8.70%
Revenue growth p.a.
56
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Humana Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$360.72 |
| 52-Wochen-Hoch | US$380.86 |
| 52-Wochen-Tief | US$163.11 |
| Beta | 0.77 |
| 1 Monat Veränderung | 17.14% |
| 3 Monate Veränderung | 109.44% |
| 1 Jahr Veränderung | 53.72% |
| 3 Jahre Veränderung | -19.19% |
| 5 Jahre Veränderung | -18.92% |
| Veränderung seit IPO | 30,158.32% |
Aktuelle Nachrichten und Updates
Analyseartikel • Jun 16
Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally
Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation. See our latest analysis for Humana. Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently...
Narrativ-Update • Jun 08
HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins
Humana's updated analyst price target has moved higher from about $210 to roughly $290, as analysts point to muted medical cost trends, potential Medicare Advantage margin recovery, and company specific Stars improvement as key supports for earnings power. Analyst Commentary Recent research shows a clear reset higher in Humana's valuation framework, with multiple firms lifting price targets and, in some cases, upgrading ratings as they reassess earnings power tied to medical cost trends and Medicare Advantage margins.Recent updates
Analyseartikel • Jun 16
Humana (HUM) Stock Could Be 78.6% Overvalued After Its Recent Rally
Humana (HUM) has drawn fresh attention after recent trading, with the stock showing a mix of short term gains and longer term declines that raises questions about how investors currently view its valuation. See our latest analysis for Humana. Recent trading has pushed Humana’s share price to $380.26, with a 30 day share price return of 24.63% and a 1 year total shareholder return of 64.10%. However, 3 and 5 year total shareholder returns remain in decline, suggesting momentum has recently...Narrativ-Update • Jun 08
HUM: Medicare Advantage Rate And Stars Uncertainty Will Pressure Margins
Humana's updated analyst price target has moved higher from about $210 to roughly $290, as analysts point to muted medical cost trends, potential Medicare Advantage margin recovery, and company specific Stars improvement as key supports for earnings power. Analyst Commentary Recent research shows a clear reset higher in Humana's valuation framework, with multiple firms lifting price targets and, in some cases, upgrading ratings as they reassess earnings power tied to medical cost trends and Medicare Advantage margins.
Narrativ-Update • May 25
HUM: Medicare Advantage Margin Recovery Will Support Future Multiple Repricing
Humana's updated analyst price target of about $371, up from roughly $322, reflects analysts' focus on stabilizing managed care trends, expectations around Medicare Advantage margin recovery, and a shift to a slightly higher discount rate and profit margin in the underlying assumptions. Analyst Commentary Recent Street research on Humana centers on how quickly Medicare Advantage margins might stabilize, how medical loss ratios track against company targets, and what that could mean for valuation as managed care trends settle.Seeking Alpha • May 18
Humana: Perhaps The 'Buy The Dip' Thesis Was Right All Along (Rating Upgrade)
Summary Humana Inc. is upgraded to Buy as shares rebound from a >65% decline, supported by improved CMS rate decisions and activist investor involvement. Despite 2026 EPS guidance below Q1 levels, HUM targets a sustainable 3%+ Medicare Advantage margin and long-term earnings growth by 2028. Recent Q1 results exceeded revenue and adjusted EPS expectations, with a favorable medical benefit ratio and affirmed 25% MA membership growth for 2026. Activist pressure and management’s focus on pricing, benefit adjustments, and operational discipline position HUM for a potential return to >$450/share by 2028. Read the full article on Seeking AlphaNarrativ-Update • May 03
HUM: Medicare Advantage Margin Execution Will Support Future Multiple Repricing
Humana's updated fair value estimate has moved from $302.11 to $322.19 as analysts adjust price targets higher across multiple firms, citing recent research that reflects revised revenue growth, margin expectations, and a higher assumed future P/E of 14.99. Analyst Commentary Recent Street research around Humana has shifted from sharp cuts earlier in the year to a cluster of higher price targets more recently.Narrativ-Update • Apr 19
HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Uncertainty
Humana's updated analyst price target edges slightly lower to about $210, as analysts balance recent target cuts tied to Medicare Advantage margin concerns with more recent upward revisions that reflect adjusted models, a modestly lower discount rate, and a slightly different profit margin and forward P/E outlook. Analyst Commentary Recent Street research on Humana reflects a split view, with some analysts revising price targets higher after updating models, while others remain cautious following earlier target cuts and rating downgrades tied to Medicare Advantage margins and CMS rate decisions.Narrativ-Update • Apr 04
HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential
Humana's updated analyst price target has shifted down from $348.00 to about $302.11, as analysts factor in lower target ranges across the Street, a higher discount rate, and cautious views on Medicare Advantage margins and earnings visibility. Analyst Commentary Recent Street research on Humana reflects a broadly cautious stance, with several firms cutting price targets and reassessing Medicare Advantage earnings power.Narrativ-Update • Mar 21
HUM: Medicare Advantage Margin Recovery Will Offset Regulatory And Cost Headwinds
Humana's updated analyst price target has been trimmed by about $12 to $212.17, as analysts factor in more cautious assumptions around Medicare Advantage margins, earnings guidance, and recent sector wide target cuts following Q4 results and regulatory news. Analyst Commentary Recent research on Humana reflects a clear reset in expectations, with price targets moving lower and ratings clustered around neutral.Narrativ-Update • Mar 07
HUM: Medicare Advantage Margin Recovery Will Drive Future Upside Potential
Our updated Humana fair value estimate moves from $287.38 to $223.88, reflecting analysts' lower price targets across the Street as they factor in uncertainty around Medicare Advantage margin improvement, EPS guidance drivers, and the profitability of recent membership growth. Analyst Commentary Recent Street research around Humana has turned more cautious, with multiple firms cutting price targets and some shifting to more neutral stances.
Narrativ-Update • Feb 21
HUM: Medicare Advantage Margin Uncertainty Will Drive A Prolonged Earnings Reset
Humana's analyst fair value estimate has been reset from about $199.74 to $146.00. This reflects a broad wave of lower price targets as analysts factor in updated EPS guidance, Medicare Advantage margin uncertainty, and recent model revisions after Q4 results and regulatory developments.Narrativ-Update • Feb 07
HUM: Policy And Margin Headwinds Will Shape A Gradual Recovery Path
Narrative Update on Humana The analyst price target for Humana has been reduced by about $18.75. Analysts point to recent downgrades, cautious reactions to CMS rate developments, and more conservative margin assumptions, even as they acknowledge potential longer term sector recovery drivers.Analyseartikel • Feb 05
Humana Inc. (NYSE:HUM) Might Not Be As Mispriced As It Looks After Plunging 30%
Humana Inc. ( NYSE:HUM ) shareholders won't be pleased to see that the share price has had a very rough month, dropping...Narrativ-Update • Jan 24
HUM: Margin And Policy Uncertainty Will Drive A More Cautious Outlook
Narrative Update Analysts have trimmed their price expectations for Humana, with the updated fair value estimate moving from about US$224 to roughly US$218. This reflects a higher discount rate, more cautious profit margin assumptions, and a lower future P/E multiple, even though modeled revenue growth is higher and recent research views are a mix of supportive and more restrained perspectives.Narrativ-Update • Jan 08
HUM: Legal Appeals And Margin Recovery Prospects Will Shape Balanced Outlook
Humana's updated analyst price target has edged down by about $1 to roughly $287. Analysts are balancing slightly higher long term revenue and margin assumptions with mixed ratings that range from Sell to Outperform across recent research.Analyseartikel • Dec 19
Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885
Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...Narrativ-Update • Dec 14
HUM: Legal Appeals And Star Ratings Will Shape Balanced Outlook Ahead
Analysts have modestly increased Humana's fair value estimate by about $2 to roughly $288, reflecting slightly stronger projected revenue growth and improved earnings visibility, even as they incorporate more conservative sector margin assumptions and ongoing concerns about Medicare Advantage and Medicaid cyclicality. Analyst Commentary Recent Street research paints a mixed picture for Humana, with modest upside to fair value supported by improving earnings visibility, but tempered by meaningful concerns around Medicare Advantage dynamics, contract diversification efforts, and broader managed care cyclicality.Analyseartikel • Dec 05
Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885
Humana Inc.'s ( NYSE:HUM ) investors are due to receive a payment of $0.885 per share on 30th of January. This payment...Narrativ-Update • Nov 30
HUM: Shares Should Rebound As Legal Efforts Progress On Medicare Bonus Cuts
Humana's analyst price target has been modestly reduced from $288.46 to $286.63. Analysts are factoring in more conservative margin assumptions following recent quarterly results and updated evaluations of the company's revenue growth and profitability outlook.Analyseartikel • Nov 16
Humana (NYSE:HUM) Has Announced A Dividend Of $0.885
Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend of $0.885 per share on the 30th of January. This...Narrativ-Update • Nov 15
HUM: Confidence Will Increase As Medicare Advantage Star Ratings Recover
Humana's analyst price target has been revised lower by approximately $7 to $288.46. Analysts cite a more cautious outlook on margins and an uneven recovery in Medicare Advantage profitability.Analyseartikel • Nov 13
Humana's (NYSE:HUM) Conservative Accounting Might Explain Soft Earnings
Investors were disappointed with the weak earnings posted by Humana Inc. ( NYSE:HUM ). However, our analysis suggests...Analyseartikel • Nov 02
Humana (NYSE:HUM) Will Pay A Dividend Of $0.885
The board of Humana Inc. ( NYSE:HUM ) has announced that it will pay a dividend on the 30th of January, with investors...Narrativ-Update • Nov 01
HUM: Medicare Advantage Stars And ACA Premiums Will Shape Balanced Near-Term Outlook
Humana's analyst price target increased slightly, rising by approximately $0.83 to $295.38. Analysts cite mixed dynamics in Medicare Advantage star ratings and improving earnings visibility as factors supporting cautious optimism.Narrativ-Update • Oct 18
AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery
Humana’s analyst price target increased slightly to $294.54 from $292.87. Analysts cite improved earnings visibility and the stability of Medicare Advantage star ratings as supporting factors for the upward revision.Narrativ-Update • Oct 04
AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery
Humana's analyst price target has fallen from approximately $299 to $293 per share, as analysts cite ongoing challenges in Medicare Advantage star ratings and a more cautious growth outlook. This comes despite recent plan diversification efforts.Narrativ-Update • Sep 05
AI, In-Home Visits, Medicaid And CenterWell Will Improve Care Delivery
Humana’s modestly higher fair value reflects improving investor sentiment, positive management commentary on future plan positioning, raised earnings guidance, and incremental legislative benefits, offset by some caution around interest rates and policy uncertainty, resulting in the consensus analyst price target rising slightly from $293.05 to $294.86. Analyst Commentary Improved investor sentiment and sector group valuations suggest estimates may have bottomed, with upcoming catalysts including government budget deals, Medicare Advantage and ACA pricing, and star ratings for future plans.Analyseartikel • Aug 26
Humana (NYSE:HUM) Has Affirmed Its Dividend Of $0.885
Humana Inc. ( NYSE:HUM ) will pay a dividend of $0.885 on the 31st of October. The dividend yield is 1.2% based on this...Analyseartikel • Aug 15
Humana Inc. (NYSE:HUM) Stocks Shoot Up 27% But Its P/E Still Looks Reasonable
NYSE:HUM 1 Year Share Price vs Fair Value Explore Humana's Fair Values from the Community and select yours Humana Inc...Seeking Alpha • Feb 12
Humana Q4 Earnings Review: A Tough Quarter -- And A Rating Downgrade
Summary Humana Inc.'s Q4 and full-year 2024 earnings report shows a 10% revenue increase but significant losses, highlighting major structural issues in its business model. Rising healthcare utilization and insufficient CMS rate increases have severely impacted Humana's profitability, with shares down 50% from their 2023 peak. New management aims to improve efficiency and service quality, but the company's future hinges on CMS rate decisions and star-rating litigation outcomes. Given the high uncertainty and potential for further losses, I recommend a “Hold” on HUM shares unless willing to take substantial risk. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Humana's Growth Vs. Rising Costs: Why It's A Hold For Cautious Investors
Summary Humana is doubling down on Medicare Advantage and healthcare services while cutting less profitable areas. Higher costs and lower profit margins are putting pressure on the business right now. Medicare Advantage growth and expanding healthcare services show long-term potential. Regulatory changes and restructuring costs could make the next couple of years bumpy. The stock looks fairly priced, so holding for now seems like the best move. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Humana, Cigna Plunge On Trump's Latest Promise: A Potential Buying Opportunity?
Summary The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability. Given the current low valuations, I reaffirm both Humana and Cigna as 'buy' candidates, as potential regulatory impacts may already be priced in. Read the full article on Seeking AlphaAktionärsrenditen
| HUM | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | -5.1% | -1.2% | -1.8% |
| 1Y | 53.7% | 19.8% | 23.3% |
Rendite im Vergleich zur Industrie: HUM übertraf die Branche US Healthcare , die im vergangenen Jahr eine Rendite von 19.8 erzielte.
Rendite vs. Markt: HUM übertraf den Markt US, der im vergangenen Jahr eine Rendite von 23.3 erzielte.
Preisvolatilität
| HUM volatility | |
|---|---|
| HUM Average Weekly Movement | 6.4% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: HUM hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: HUMDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1961 | 67,060 | Jim Rechtin | www.humana.com |
Humana Inc. bietet medizinische und spezielle Versicherungsprodukte in den Vereinigten Staaten an. Das Unternehmen ist in zwei Segmenten tätig: Insurance und CenterWell. Das Versicherungssegment bietet individuelle Medicare Advantage-Produkte an, einschließlich Krankenversicherungsleistungen, einschließlich Wellness-Programmen, Management chronischer Erkrankungen und Pflegekoordination; individuelle Medicare-Stand-alone-Produkte für verschreibungspflichtige Medikamente (PDP); Gruppenprodukte für Medicare Advantage und Medicare-Stand-alone-PDP; Medicare-Zusatzversicherungen; Spezial- und Zusatzversicherungen, die Zahn-, Seh-, Lebens- und Berufsunfähigkeitsversicherungen umfassen; sowie Verwaltungsdienste zur Vermittlung von Gesundheitsleistungen für aktive und pensionierte Militärangehörige und deren Angehörige sowie Apotheken-Leistungsmanager.
Humana Inc.'s Grundlagenzusammenfassung
| HUM grundlegende Statistiken | |
|---|---|
| Marktanteil | US$43.30b |
| Gewinn(TTM) | US$1.13b |
| Umsatz(TTM) | US$137.20b |
38.3x
Kurs-Gewinn-Verhältnis 0.3x
Kurs-Umsatz-VerhältnisIst HUM zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| HUM Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$137.20b |
| Kosten der Einnahmen | US$117.98b |
| Bruttogewinn | US$19.22b |
| Sonstige Ausgaben | US$18.09b |
| Gewinn | US$1.13b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 29, 2026
| Gewinn per Aktie (EPS) | 9.41 |
| Bruttomarge | 14.01% |
| Nettogewinnspanne | 0.82% |
| Schulden/Eigenkapital-Verhältnis | 77.1% |
Wie hat sich HUM auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
1.0%
Aktuelle Dividendenrendite38%
AusschüttungsquoteZahlt HUM eine zuverlässige Dividende?
Siehe HUM Dividendenhistorie und Benchmarks| Humana Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jun 26 2026 |
| Datum der Dividendenzahlung | Jul 31 2026 |
| Tage bis Ex-Dividende | 2 days |
| Tage bis zum Datum der Dividendenzahlung | 37 days |
Zahlt HUM eine zuverlässige Dividende?
Siehe HUM Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/22 15:28 |
| Aktienkurs zum Tagesende | 2026/06/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Humana Inc. wird von 37 Analysten beobachtet. 21 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Hua Ha | Baird |
| Andrew Mok | Barclays |